These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 37524847)

  • 21. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
    Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
    CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review.
    Mohiuddin S; Maraka S; Usman Baig M; Gupta S; Muzzafar T; Valyi-Nagy T; Lindsay H; Moody K; Razvi S; Paulino A; Slavin K; Gondi V; McCutcheon I; Zaky W; Khatua S
    J Clin Neurosci; 2021 Jul; 89():405-411. PubMed ID: 34053821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to treat histone 3 altered gliomas: molecular landscape and therapeutic developments.
    Di Nunno V; Franceschi E; Gatto L; Tosoni A; Bartolini S; Brandes AA
    Expert Rev Clin Pharmacol; 2023 Jan; 16(1):17-26. PubMed ID: 36576307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Picca A; Berzero G; Bielle F; Touat M; Savatovsky J; Polivka M; Trisolini E; Meunier S; Schmitt Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Di Stefano AL; Sanson M
    Neurology; 2018 Jun; 90(23):e2086-e2094. PubMed ID: 29728520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
    Handis C; Tanrıkulu B; Danyeli AE; Özek MM
    Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of H3K27M mutation status of diffuse midline gliomas using MRI features.
    Chauhan RS; Kulanthaivelu K; Kathrani N; Kotwal A; Bhat MD; Saini J; Prasad C; Chakrabarti D; Santosh V; Uppar AM; Srinivas D
    J Neuroimaging; 2021 Nov; 31(6):1201-1210. PubMed ID: 34189806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. H3F3A K27M mutations in thalamic gliomas from young adult patients.
    Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
    Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy plus temozolomide with or without anlotinib in H3K27M-mutant diffuse midline glioma: A retrospective cohort study.
    Liu C; Kuang S; Huang T; Wu J; Zhang L; Gong X
    CNS Neurosci Ther; 2024 Apr; 30(4):e14730. PubMed ID: 38644565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
    Vuong HG; Ngo TNM; Le HT; Dunn IF
    J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
    López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
    J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy in H3K27M diffuse midline glioma.
    Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
    Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
    [TBL] [Abstract][Full Text] [Related]  

  • 36. H3K27M mutant glioma: Disease definition and biological underpinnings.
    Saratsis AM; Knowles T; Petrovic A; Nazarian J
    Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review.
    Navarro RE; Golub D; Hill T; McQuinn MW; William C; Zagzag D; Hidalgo ET
    Childs Nerv Syst; 2021 Jul; 37(7):2347-2356. PubMed ID: 32989496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas.
    Kambhampati M; Panditharatna E; Yadavilli S; Saoud K; Lee S; Eze A; Almira-Suarez MI; Hancock L; Bonner ER; Gittens J; Stampar M; Gaonkar K; Resnick AC; Kline C; Ho CY; Waanders AJ; Georgescu MM; Rance NE; Kim Y; Johnson C; Rood BR; Kilburn LB; Hwang EI; Mueller S; Packer RJ; Bornhorst M; Nazarian J
    Sci Rep; 2020 Jul; 10(1):10954. PubMed ID: 32616776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death.
    Ahrendsen JT; Sinai C; Meredith DM; Malinowski SW; Cooney TM; Bandopadhayay P; Ligon KL; Alexandrescu S
    J Neuropathol Exp Neurol; 2021 Nov; 80(11):1052–1059. PubMed ID: 34580728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.